Revision as of 03:24, 11 November 2019 editPatapsco913 (talk | contribs)Autopatrolled, Extended confirmed users166,699 edits →Early life and education← Previous edit | Revision as of 11:41, 21 December 2019 edit undoCoffee (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers48,540 edits →Early life and education: removing blatant WP:SYNTH/WP:BLP/WP:BLPCAT/WP:OR violation, nowhere in the source does it mention her birth, nor does that source confer this person is anything other than the founder of Caribou Biosciences as it is not clear from a verified consensus of sources that this person identifies this way, nor is it clear the source is referring to ethnicity or religion - do not readd such a claim without proper sourcing (WP:BLPREMOVE)Next edit → | ||
Line 28: | Line 28: | ||
== Early life and education == | == Early life and education == | ||
Haurwitz was born |
Haurwitz was born on May 20, 1985.{{cn}} She grew up in ], ]. Her mother is elementary school teacher and her father, an environmental journalist. She self describes her younger self as "your average science nerd." While in high school, Haurwitz kept 400 '']'' in the family's dining room to conduct ] experiments.<ref name=":1">{{Cite news|url=https://www.ozy.com/rising-stars/this-scientist-turned-ceo-wants-to-gene-edit-a-way-to-cure-cancer/85243#.WrBcvXemsnU.twitter|title=This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer|last=Fosco|first=Molly|date=2018-03-16|work=OZY|access-date=2018-09-05|language=en}}</ref> | ||
Haurwitz began researching RNA during her undergraduate years.<ref>{{Cite news|url=https://www.statnews.com/2016/06/22/rachel-haurwitz-crispr-caribou/|title=For biotech CEO Rachel Haurwitz, CRISPR is big business|last=Herman|first=Elizabeth D.|date=2016-06-22|work=STAT|access-date=2018-09-05|language=en-US}}</ref> She attended ] where she earned an undergraduate degree. In 2007, she began doctoral studies at ]. At the age of 21,<ref>{{Cite news|url=https://mpnforum.com/the-two-faces-of-rachel-haurwitz/|title=The two faces of Rachel Haurwitz|last=|first=|date=2015-04-09|work=MPNforum Magazine|access-date=2018-09-05|language=en-US}}</ref> Haurwitz began working as a graduate student in ]'s laboratory, in 2008 where she completed her doctorate in molecular and cell biology.<ref name=":2">{{Cite news|url=https://techcrunch.com/2018/09/04/these-two-crispr-experts-are-coming-to-disrupt-sf-2018/|title=These two CRISPR experts are coming to Disrupt SF 2018|last=Buhr|first=Sarah|date=2018-09-04|work=TechCrunch|access-date=2018-09-05|language=en-US}}</ref> Haurwitz originally intended on becoming an intellectual property lawyer for biotechnology patents but later chose to continue pursuing science.<ref name=":3">{{Cite news|url=http://fortune.com/40-under-40/2016/rachel-haurwitz-23/|title=40 Under 40|last=|first=|date=2016-09-22|work=Fortune|access-date=2018-09-05|language=en-US}}</ref> | Haurwitz began researching RNA during her undergraduate years.<ref>{{Cite news|url=https://www.statnews.com/2016/06/22/rachel-haurwitz-crispr-caribou/|title=For biotech CEO Rachel Haurwitz, CRISPR is big business|last=Herman|first=Elizabeth D.|date=2016-06-22|work=STAT|access-date=2018-09-05|language=en-US}}</ref> She attended ] where she earned an undergraduate degree. In 2007, she began doctoral studies at ]. At the age of 21,<ref>{{Cite news|url=https://mpnforum.com/the-two-faces-of-rachel-haurwitz/|title=The two faces of Rachel Haurwitz|last=|first=|date=2015-04-09|work=MPNforum Magazine|access-date=2018-09-05|language=en-US}}</ref> Haurwitz began working as a graduate student in ]'s laboratory, in 2008 where she completed her doctorate in molecular and cell biology.<ref name=":2">{{Cite news|url=https://techcrunch.com/2018/09/04/these-two-crispr-experts-are-coming-to-disrupt-sf-2018/|title=These two CRISPR experts are coming to Disrupt SF 2018|last=Buhr|first=Sarah|date=2018-09-04|work=TechCrunch|access-date=2018-09-05|language=en-US}}</ref> Haurwitz originally intended on becoming an intellectual property lawyer for biotechnology patents but later chose to continue pursuing science.<ref name=":3">{{Cite news|url=http://fortune.com/40-under-40/2016/rachel-haurwitz-23/|title=40 Under 40|last=|first=|date=2016-09-22|work=Fortune|access-date=2018-09-05|language=en-US}}</ref> |
Revision as of 11:41, 21 December 2019
Rachel Haurwitz | |
---|---|
Born | Rachel Elizabeth Haurwitz (1985-05-20) May 20, 1985 (age 39) Austin, Texas, U.S. |
Alma mater |
|
Scientific career | |
Fields | Biochemistry |
Institutions | Caribou Biosciences |
Thesis | The CRISPR endoribonuclease Csy4 utilizes unusual sequence- and structure-specific mechanisms to recognize and process crRNAs (2012) |
Doctoral advisor | Jennifer Doudna |
Other academic advisors | Jillian Banfield |
Rachel Elizabeth Haurwitz (born May 20, 1985) is an American biochemist and structural biologist. She is the co-founder, chief executive officer, and president of Caribou Biosciences, a gene editing company.
Early life and education
Haurwitz was born on May 20, 1985. She grew up in Austin, Texas. Her mother is elementary school teacher and her father, an environmental journalist. She self describes her younger self as "your average science nerd." While in high school, Haurwitz kept 400 planaria in the family's dining room to conduct maze experiments.
Haurwitz began researching RNA during her undergraduate years. She attended Harvard College where she earned an undergraduate degree. In 2007, she began doctoral studies at University of California, Berkeley. At the age of 21, Haurwitz began working as a graduate student in Jennifer Doudna's laboratory, in 2008 where she completed her doctorate in molecular and cell biology. Haurwitz originally intended on becoming an intellectual property lawyer for biotechnology patents but later chose to continue pursuing science.
Career
In 2011, Haurwitz and Doudna co-founded Caribou Biosciences, a gene editing spinout-startup company. Haurwitz is the company's CEO and president. She holds several patents for CRISPR-based technologies. Caribou Biosciences was initially housed in the basement of the same building that housed Doudna's laboratory. Haurwitz's company supports the commercialization of CRISPR technology in healthcare and agriculture. Its researchers explore issues in antimicrobial resistance, food scarcity, and vaccine shortages. The company licensed Berkeley's CRISPR patent and deals with agricultural and pharmaceutical companies and research firms. As of 2018 she oversees 46 employees. In 2018, Haurwitz announced that Caribou Biosciences was shifting focus on medicine and developing cancer therapies targeting microbes.
On being a woman executive, Haurwitz reports that she has experienced situations where she was treated differently because of her gender. She also states that she more frequently felt underestimated because of her young age.
Awards and honors
- 2014 Forbes 30 Under 30
- April 2018 Association for Women in Science Next Generation Award
- November 2018 Forbes' America's Top 50 Women In Tech
Personal life
She is a long-distance runner and is training for a marathon. Haurwitz knits as a hobby.
Selected works
Papers
- Haurwitz, Rachel E.; Jinek, Martin; Wiedenheft, Blake; Zhou, Kaihong; Doudna, Jennifer A. (September 10, 2010). "Sequence- and Structure-Specific RNA Processing by a CRISPR Endonuclease". Science. 329 (5997): 1355–1358. doi:10.1126/science.1192272. PMC 3133607. PMID 20829488.
- Qi, Lei; Haurwitz, Rachel E; Shao, Wenjun; Doudna, Jennifer A; Arkin, Adam P (September 16, 2012). "RNA processing enables predictable programming of gene expression". Nature Biotechnology. 30 (10): 1002–1006. doi:10.1038/nbt.2355. PMID 22983090.
References
- ^ Fosco, Molly (March 16, 2018). "This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer". OZY. Retrieved September 5, 2018.
- Herman, Elizabeth D. (June 22, 2016). "For biotech CEO Rachel Haurwitz, CRISPR is big business". STAT. Retrieved September 5, 2018.
- "The two faces of Rachel Haurwitz". MPNforum Magazine. April 9, 2015. Retrieved September 5, 2018.
- ^ Buhr, Sarah (September 4, 2018). "These two CRISPR experts are coming to Disrupt SF 2018". TechCrunch. Retrieved September 5, 2018.
- ^ "40 Under 40". Fortune. September 22, 2016. Retrieved September 5, 2018.
- "Rachel Haurwitz". Forbes. Retrieved September 5, 2018.
- Leeming, Jack (April 5, 2018). "How researchers are ensuring that their work has an impact". Nature. 556 (7699): 139–141. doi:10.1038/d41586-018-03925-8. ISSN 0028-0836. PMID 29620739.
- ^ "NOMINEE: Rachel Haurwitz". Newsweek. January 18, 2018. Retrieved September 5, 2018.
- Regalado, Antonio (2017). "One woman's ascent from lab rat to CEO of a CRISPR company". MIT Technology Review. Retrieved September 5, 2018.
- "Women who lead in life sciences". San Francisco Business Times. Bizjournals. 2018. Retrieved September 5, 2018.
- "30 Under 30 2017: All-Star Alumni". Forbes.
- "Association for Women in Science Announces Top Awards for STEM and Gender Equity Champions". Association for Women in Science.
- "Rachel Haurwitz". Forbes.
- University of California, Berkeley alumni
- Harvard College alumni
- American women biochemists
- American women biologists
- 21st-century American chemists
- 21st-century women scientists
- Scientists from Texas
- People from Austin, Texas
- 1985 births
- Living people
- 21st-century American biologists
- Jewish American scientists
- American women chief executives
- American women company founders
- 21st-century American businesspeople
- 21st-century American women
- 21st-century businesswomen
- Jewish women scientists
- Jewish women in business